Cargando…

Recombinant human ACE2: potential therapeutics of SARS-CoV-2 infection and its complication

Detalles Bibliográficos
Autores principales:	Pang, Xiaocong, Cui, Yimin, Zhu, Yizhun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313652/ https://www.ncbi.nlm.nih.gov/pubmed/32581256 http://dx.doi.org/10.1038/s41401-020-0430-6

Ejemplares similares

Potential Anionic Substances Binding to Platelet Factor 4 in Vaccine-Induced Thrombotic Thrombocytopenia of ChAdOx1-S Vaccine for SARS-CoV-2
por: Pang, Xiaocong, et al.
Publicado: (2022)

Single-Cell RNA Expression Profiling of ACE2, the Receptor of SARS-CoV-2
por: Zhao, Yu, et al.
Publicado: (2020)

ACE2 expression is regulated by AhR in SARS-CoV-2-infected macaques
por: Lv, Jiadi, et al.
Publicado: (2021)

Structures of ACE2–SIT1 recognized by Omicron variants of SARS-CoV-2
por: Shen, Yaping, et al.
Publicado: (2022)

Identification and characterization of a monoclonal antibody blocking the SARS-CoV-2 spike protein–ACE2 interaction
por: Yuan, MengYa, et al.
Publicado: (2021)

Tobacco Smoking Increases the Lung Gene Expression of ACE2, the Receptor of SARS-CoV-2
por: Cai, Guoshuai, et al.
Publicado: (2020)

Pyroptosis of syncytia formed by fusion of SARS-CoV-2 spike and ACE2-expressing cells
por: Ma, Huabin, et al.
Publicado: (2021)

Combustible and Electronic Cigarette Exposures Increase ACE2 Activity and SARS-CoV-2 Spike Binding
por: Ghosh, Arunava, et al.
Publicado: (2021)

Cryo-EM structures of SARS-CoV-2 BA.2-derived subvariants spike in complex with ACE2 receptor
por: Li, Yaning, et al.
Publicado: (2023)

hACE2 Fc-neutralization antibody cocktail provides synergistic protection against SARS-CoV-2 and its spike RBD variants
por: Liu, Junli, et al.
Publicado: (2021)

Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations
por: Cao, Yanan, et al.
Publicado: (2020)

Efficient antibody evasion but reduced ACE2 binding by the emerging SARS-CoV-2 variant B.1.640.2
por: Arora, Prerna, et al.
Publicado: (2022)

Smoking increases expression of the SARS-CoV-2 spike protein-binding long ACE2 isoform in bronchial epithelium
por: Pouwels, Simon D., et al.
Publicado: (2023)

Blockade of SARS-CoV-2 infection by recombinant soluble ACE2
por: Alhenc-Gelas, Francois, et al.
Publicado: (2020)

Deltacron is a recombinant variant of SARS-CoV-2 but not a laboratory mistake
por: Karbalaei, Mohsen, et al.
Publicado: (2022)

Expression of ACE2—a Key SARS-CoV-2 Entry Factor—Is Not Increased in the Nasal Mucosa of People with Cystic Fibrosis
por: Sala, Marc A., et al.
Publicado: (2022)

Therapeutic Strategies for SARS-CoV-2 acting on ACE-2
por: Vitiello, A., et al.
Publicado: (2021)

Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics
por: Standl, Fabian, et al.
Publicado: (2021)

Deepening Pathology of SARS-CoV-2 Pneumonia Explains Lung Ventilation Complications
por: Manenti, Antonio, et al.
Publicado: (2022)

Consider Transverse Myelitis as a Complication of a SARS-CoV-2 Vaccination
por: Finsterer, Josef, et al.
Publicado: (2022)

Cardiovascular Complications Are the Executioners of Inpatient With SARS-CoV-2 Community-Acquired Pneumonia
por: Zeng, Guangting
Publicado: (2023)

Ebselen, a new candidate therapeutic against SARS-CoV-2
por: Haritha, C.V., et al.
Publicado: (2020)

SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings
por: Kalra, Rajkumar Singh, et al.
Publicado: (2020)

SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity
por: Ramanathan, Muthukumar, et al.
Publicado: (2021)

The glycosylation in SARS-CoV-2 and its receptor ACE2
por: Gong, Yanqiu, et al.
Publicado: (2021)

Recombinant SARS-CoV-2 variants XD, XE, and XF: The emergence of recombinant variants requires an urgent call for research – Correspondence
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1
por: van Doremalen, Neeltje, et al.
Publicado: (2020)

Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies
por: Yamasoba, Daichi, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig
por: Lei, Changhai, et al.
Publicado: (2020)

Ceftazidime exhibits a broad inhibition to the infection of SARS-CoV-2 prototype and Omicron variant in vitro by blocking spike protein-ACE2 interaction
por: Zheng, Yun-zhe, et al.
Publicado: (2023)

Sunitinib reduces the infection of SARS-CoV, MERS-CoV and SARS-CoV-2 partially by inhibiting AP2M1 phosphorylation
por: Wang, Pei-Gang, et al.
Publicado: (2020)

Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo
por: Zhang, Zhaoyong, et al.
Publicado: (2021)

Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
por: Zang, Jinkai, et al.
Publicado: (2020)

SARS-CoV-2 shedding and infectivity
por: Atkinson, Barry, et al.
Publicado: (2020)

The proximal origin of SARS-CoV-2
por: Andersen, Kristian G., et al.
Publicado: (2020)

SARS-CoV-2 Infection in Children
por: Lu, Xiaoxia, et al.
Publicado: (2020)

SARS-CoV-2 seroprevalence in Spain
por: George, Thukalan Paulose
Publicado: (2020)

SARS CoV2 vaccine and aphasia
por: sookaromdee, Pathum, et al.
Publicado: (2021)

Hybrid SARS-CoV-2 variants
por: Rahimi, Farid, et al.
Publicado: (2022)

SARS-CoV-2 seroprevalence in Spain
por: Hoffmann, Christian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7e7pe9pm1r6dtpu52j25pop63q